BTD Regimen May Be Viable Salvage Option for Multiple Myeloma

Share this content:
Bendamustine plus thalidomide and dexamethasone may be a viable salvage option for the treatment of double-relapsed/refractory multiple myeloma.
Bendamustine plus thalidomide and dexamethasone may be a viable salvage option for the treatment of double-relapsed/refractory multiple myeloma.

Bendamustine plus thalidomide and dexamethasone may be a viable salvage option for the treatment of patients with double-relapsed/refractory multiple myeloma, a recent study published in the journal Annals of Hematology has shown.

For the study, researchers retrospectively analyzed data from 30 patients with double-relapsed/refractory multiple myeloma who received bendamustine with a cumulative dose up to 200 mg/m2, thalidomide 50-150 mg daily as tolerated, and dexamethasone 160 mg/cycle in 28-day cycles. Patients received a median of 5 cycles.

RELATED: Revlimid with Dexamethasone Approved for Newly Diagnosed Multiple Myeloma

Results showed that 87% of patients achieved stable disease or better. Median progression-free survival and overall survival were 4.0 and 7.2 months, respectively, at a median follow-up of 12.1 months. 

In regard to safety, the most common grade 3-4 adverse events were neutropenia, thrombocytopenia, and anemia. Other common treatment-associated side effects were infection, pain, and sensory neuropathy.

Reference

  1. Lau I-J, Smith D, Aitchison R, et al. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol. 2015;94(4):643-649.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters